Theory Paper IIDrNB Cardiology – Theory Notes
ASSESSMENT FOR CORONARY REVASCULARIZATION IN IHD WITH SEVERE LVSD (LVEF ≤ 35%)
ICORE CLINICAL PARADIGM AND INITIAL GDMT OPTIMIZATION
- Decoupling Prognostic Survival Benefit from Symptomatic Relief: In patients with Ischemic Cardiomyopathy (ICM) and severe Left Ventricular Systolic Dysfunction (LVEF 35 percent or less), revascularization decision-making by the multidisciplinary Heart Team must strictly distinguish survival benefit (achieved with CABG over long-term follow-up) from angina relief (achieved with either CABG or PCI).
- Mandatory Upfront Quadruple GDMT Optimization (Class I): Prior to or alongside revascularization evaluation, all patients must be initiated and titrated on foundational Four-Pillar HFrEF Guideline-Directed Medical Therapy (GDMT): ARNI (Sacubitril/Valsartan) or ACEi/ARB, Evidence-Based Beta-Blockers (Carvedilol, Metoprolol Succinate, Bisoprolol), Mineralocorticoid Receptor Antagonists (Spironolactone, Eplerenone), and SGLT2 Inhibitors (Dapagliflozin, Empagliflozin).
- Invasive Coronary Angiography and Target Vessel Assessment (Class I): Defines anatomical complexity (SYNTAX Score), presence of Left Main or proximal LAD / 3-vessel disease, and most critically the caliber and runoff quality of the distal epicardial target vessels, which determines whether surgical bypass grafts can remain patent.
IITHE REDEFINED ROLE OF MYOCARDIAL VIABILITY AND ISCHEMIA TESTING
- Pathophysiological Concept of “Hibernating Myocardium” (Rahimtoola): Chronically hypoperfused yet living myocytes downregulate contractile function to match reduced oxygen supply (hibernation), which is potentially reversible upon restoring blood flow, in contrast to irreversible collagen scar.
- Non-Invasive Viability Modalities and Diagnostic Thresholds:
- Late Gadolinium Enhancement Cardiac MRI (LGE-CMR — Gold Standard for Scar Transmurality): Segments with LGE transmurality less than 50 percent of wall thickness (and preserved end-diastolic wall thickness >=5.5 to 6.0 mm) have a high likelihood (>70%) of functional contractile recovery after revascularization, whereas segments with >50 percent transmural LGE represent non-viable scar (<10% recovery).
- 18F-FDG PET + Perfusion Imaging (Most Sensitive Modality): Identifies hibernating myocardium via “Perfusion-Metabolism Mismatch” (reduced resting perfusion on Rb-82/N-13 ammonia or SPECT coupled with preserved or enhanced 18F-FDG glucose uptake), whereas concordantly reduced perfusion and FDG uptake (“Match”) indicates non-viable scar.
- Low-Dose Dobutamine Stress Echocardiography (DSE — Most Specific Modality): Demonstrates a “Biphasic Response”—contractile improvement in akinetic/hypokinetic segments at low-dose dobutamine (5 to 10 mcg/kg/min) (confirming contractile reserve) followed by worsening wall motion at peak high-dose dobutamine (20 to 40 mcg/kg/min) (confirming inducible ischemia in a viable jeopardized territory), which has the highest positive predictive value for LVEF recovery.
- The Landmark Viability Paradigm Shift (STICH & REVIVED-BCIS2 Viability Substudies):
- STICH Viability Substudy (Bonow et al., NEJM 2011 & Panza et al., NEJM 2019): Proved that the presence or absence of myocardial viability does NOT statistically interact with or predict the long-term survival benefit of CABG over medical therapy alone; furthermore, even though viable myocardium was associated with some improvement in LVEF, change in LVEF did not mediate improved survival.
- REVIVED-BCIS2 Viability Substudy (Perera et al., JAMA Cardiol 2023): Confirmed that extent of viable myocardium did NOT identify any subgroup deriving survival, heart failure, or LVEF benefit from PCI; instead, total scar burden (LGE percentage on CMR) was the strongest independent predictor of mortality and arrhythmias regardless of treatment arm.
- Current Guideline Stance (ESC 2024 CCS / ACC-AHA 2021): Non-invasive viability testing is Class IIb—useful selectively to verify that akinetic/aneurysmal territories subtended by diseased target vessels are not 100% transmural scar before grafting/stenting in high-risk candidates, but absence of viability alone must never be used to deny CABG to an anatomically suitable surgical candidate.
IIIREVASCULARIZATION MODALITIES AND LANDMARK TRIAL EVIDENCE
| Revascularization Modality | Guideline Class (ESC 2024 CCS / ACC-AHA 2021-2023) | Landmark Trial & Primary Outcome | Mechanistic Explanation (“Why CABG Beats PCI in ICM”) |
|---|---|---|---|
| CABG + GDMT (Acceptable surgical risk & graftable distal targets) | Class I (Level B): First-line revascularization strategy to improve long-term survival in multivessel CAD + LVEF <=35% | STICHES (10-Year STICH Extension, NEJM 2016): CABG reduced all-cause mortality by 16% (58.9% vs. 66.1%; HR 0.84; p = 0.02; NNT = 14; +1.4 yr median survival) and CV mortality by 21% (HR 0.79) | Surgical “Collateralization”: A bypass graft (especially LIMA-to-LAD) is anastomosed to the mid/distal vessel, bypassing the entire proximal 5–6 cm “vulnerable plaque zone” and protecting against future fatal spontaneous Type 1 MIs |
| PCI + GDMT (High/prohibitive surgical risk or patient preference) | Class IIb (ESC 2024) / Class IIa for refractory angina: Alternative to CABG after Heart Team review; NOT indicated purely to improve survival in stable non-anginal ICM | REVIVED-BCIS2 (NEJM 2022, n = 700, LVEF <=35% + BCIS-Jeopardy Score >=6 + proven viability): PCI + OMT failed to reduce all-cause death or HF hospitalization (37.2% vs. 38.0%; HR 0.99; p = 0.96) and did not improve LVEF at 6 or 12 months | Focal Lesion Treatment: Stents treat only focal flow-limiting stenoses while leaving adjacent non-obstructive vulnerable plaques unprotected in a diffusely diseased tree, while carrying periprocedural Type 4a MI risk |
- The STICH Trial Surgical Timing Caveat (The “Early Hazard vs. Late Payoff” Rule): In the original 5-year STICH Trial (NEJM 2011, n = 1,212, LVEF <=35%), CABG incurred a higher early (30-day) perioperative mortality that took 2 years to cross over, narrowly missing statistical significance for all-cause mortality at 5 years (p = 0.12) before achieving a definitive, highly significant 16 percent all-cause mortality reduction and 28 percent reduction in death or CV hospitalization at 10 years in STICHES (NEJM 2016) (with greatest benefit in patients with all three prognostic factors: 3-vessel CAD, LVEF <27%, and LVESVi >79 mL/m2, and in patients under 60 to 65 years of age).
- Surgical Ventricular Reconstruction (SVR / Dor Procedure — STICH Hypothesis 2, NEJM 2009): Adding routine surgical anterior left ventricular aneurysm plication/reconstruction to CABG reduced LV end-systolic volume by 19 percent (vs. 6 percent with CABG alone) but produced zero improvement in symptoms, exercise tolerance, death, or cardiac hospitalization, so routine SVR is not recommended unless required to resect a large, distinct dyskinetic true aneurysm causing refractory heart failure, mural thromboembolism, or incessant ventricular tachycardia.
IVPRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT
- The Diffuse Diabetic Small-Vessel Phenotype: Indian patients present with ischemic cardiomyopathy at a younger age (often in the 50s—the younger age group in which STICHES showed the greatest 10-year survival benefit from CABG), but frequently exhibit a malignant diabetic coronary phenotype characterized by diffuse tandem atherosclerosis, heavy calcification, and small distal reference vessel diameters (<2.0 to 2.25 mm).
- Heart Team Navigation of “Poor Distal Targets”: When diffuse distal LAD/coronary disease renders surgical grafting anatomically unfeasible (or when advanced frailty/CKD/cirrhosis yields a prohibitive STS/EuroSCORE II), the Heart Team prioritizes aggressive Quadruple GDMT + CRT/ICD (if indicated), reserving intravascular-imaging-guided Complex High-Risk Indicated PCI (CHIP) (with rotational atherectomy/IVL and hemodynamic IABP/Impella support when needed) strictly for patients with limiting angina or acute coronary syndrome presentations rather than stable asymptomatic LV dysfunction.
Key references
- Velazquez EJ, Lee KL, Jones RH, et al. (STICHES Investigators): Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy (10-Year Follow-Up of the STICH Trial), New England Journal of Medicine, 2016.
- Perera D, Clayton T, O’Kane PD, et al. (REVIVED-BCIS2 Investigators): Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction, New England Journal of Medicine, 2022.
- Bonow RO, Maurer G, Lee KL, et al. (STICH Trial Investigators): Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction, New England Journal of Medicine, 2011.
- Vrints C, Andreotti F, Koskinas KC, et al.: 2024 ESC Guidelines for the management of chronic coronary syndromes, European Heart Journal, 2024.
meritmedscript.comDr. Sidhartha Mullapudi
